ULTRAGENYX PHARMACEUTICAL IN (RARE)

US90400D1081 - Common Stock

43.605  +0.13 (+0.31%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to RARE. RARE was compared to 568 industry peers in the Biotechnology industry. While RARE seems to be doing ok healthwise, there are quite some concerns on its profitability. RARE is valued quite expensive, but it does show an excellent growth.



1

1. Profitability

1.1 Basic Checks

In the past year RARE has reported negative net income.
In the past year RARE has reported a negative cash flow from operations.
In the past 5 years RARE always reported negative net income.
In the past 5 years RARE always reported negative operating cash flow.

1.2 Ratios

RARE has a better Return On Assets (-36.34%) than 60.88% of its industry peers.
With a Return On Equity value of -161.17%, RARE is not doing good in the industry: 65.49% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -36.34%
ROE -161.17%
ROIC N/A
ROA(3y)-38.76%
ROA(5y)-32.47%
ROE(3y)-156.72%
ROE(5y)-109.58%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

RARE has a better Gross Margin (86.25%) than 89.38% of its industry peers.
RARE's Gross Margin has declined in the last couple of years.
RARE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.86%
GM growth 5Y-1.71%

6

2. Health

2.1 Basic Checks

RARE does not have a ROIC to compare to the WACC, probably because it is not profitable.
RARE has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RARE has more shares outstanding
RARE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

RARE has an Altman-Z score of -1.87. This is a bad value and indicates that RARE is not financially healthy and even has some risk of bankruptcy.
RARE has a Altman-Z score of -1.87. This is comparable to the rest of the industry: RARE outperforms 53.63% of its industry peers.
There is no outstanding debt for RARE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.87
ROIC/WACCN/A
WACC11.83%

2.3 Liquidity

RARE has a Current Ratio of 2.81. This indicates that RARE is financially healthy and has no problem in meeting its short term obligations.
RARE has a Current ratio of 2.81. This is in the lower half of the industry: RARE underperforms 67.26% of its industry peers.
RARE has a Quick Ratio of 2.65. This indicates that RARE is financially healthy and has no problem in meeting its short term obligations.
RARE has a worse Quick ratio (2.65) than 67.96% of its industry peers.
Industry RankSector Rank
Current Ratio 2.81
Quick Ratio 2.65

7

3. Growth

3.1 Past

RARE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.87%, which is quite impressive.
The Revenue has grown by 27.44% in the past year. This is a very strong growth!
Measured over the past years, RARE shows a very strong growth in Revenue. The Revenue has been growing by 53.17% on average per year.
EPS 1Y (TTM)27.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.22%
Revenue 1Y (TTM)27.44%
Revenue growth 3Y17.02%
Revenue growth 5Y53.17%
Sales Q2Q%42.27%

3.2 Future

RARE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.95% yearly.
Based on estimates for the next years, RARE will show a very strong growth in Revenue. The Revenue will grow by 36.89% on average per year.
EPS Next Y24.59%
EPS Next 2Y17.35%
EPS Next 3Y17.57%
EPS Next 5Y21.95%
Revenue Next Year26.48%
Revenue Next 2Y22.48%
Revenue Next 3Y26.68%
Revenue Next 5Y36.89%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

0

4. Valuation

4.1 Price/Earnings Ratio

RARE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RARE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as RARE's earnings are expected to grow with 17.57% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.35%
EPS Next 3Y17.57%

0

5. Dividend

5.1 Amount

RARE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ULTRAGENYX PHARMACEUTICAL IN

NASDAQ:RARE (12/20/2024, 1:12:33 PM)

43.605

+0.13 (+0.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2024-11-05/amc
Earnings (Next)02-13 2025-02-13/amc
Inst Owners93.61%
Inst Owner Change-2.59%
Ins Owners1.95%
Ins Owner Change1.63%
Market Cap4.03B
Analysts85.19
Price Target94.28 (116.21%)
Short Float %3.84%
Short Ratio4.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.69%
Min EPS beat(2)5.37%
Max EPS beat(2)12.01%
EPS beat(4)3
Avg EPS beat(4)2.61%
Min EPS beat(4)-14.94%
Max EPS beat(4)12.01%
EPS beat(8)4
Avg EPS beat(8)-1.94%
EPS beat(12)4
Avg EPS beat(12)-15.33%
EPS beat(16)6
Avg EPS beat(16)-11.52%
Revenue beat(2)2
Avg Revenue beat(2)8.87%
Min Revenue beat(2)0.71%
Max Revenue beat(2)17.02%
Revenue beat(4)3
Avg Revenue beat(4)3.58%
Min Revenue beat(4)-8.03%
Max Revenue beat(4)17.02%
Revenue beat(8)4
Avg Revenue beat(8)-0.78%
Revenue beat(12)5
Avg Revenue beat(12)-1.88%
Revenue beat(16)7
Avg Revenue beat(16)1.78%
PT rev (1m)0.88%
PT rev (3m)2.93%
EPS NQ rev (1m)0.85%
EPS NQ rev (3m)12.98%
EPS NY rev (1m)0.69%
EPS NY rev (3m)2.06%
Revenue NQ rev (1m)-0.07%
Revenue NQ rev (3m)3.79%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)1.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.7
P/FCF N/A
P/OCF N/A
P/B 11.61
P/tB 29.29
EV/EBITDA N/A
EPS(TTM)-6.47
EYN/A
EPS(NY)-5.19
Fwd EYN/A
FCF(TTM)-4.76
FCFYN/A
OCF(TTM)-4.53
OCFYN/A
SpS5.66
BVpS3.76
TBVpS1.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.34%
ROE -161.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.25%
FCFM N/A
ROA(3y)-38.76%
ROA(5y)-32.47%
ROE(3y)-156.72%
ROE(5y)-109.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.86%
GM growth 5Y-1.71%
F-Score5
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.36%
Cap/Sales 4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.81
Quick Ratio 2.65
Altman-Z -1.87
F-Score5
WACC11.83%
ROIC/WACCN/A
Cap/Depr(3y)511.28%
Cap/Depr(5y)436.55%
Cap/Sales(3y)23.93%
Cap/Sales(5y)22.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.22%
EPS Next Y24.59%
EPS Next 2Y17.35%
EPS Next 3Y17.57%
EPS Next 5Y21.95%
Revenue 1Y (TTM)27.44%
Revenue growth 3Y17.02%
Revenue growth 5Y53.17%
Sales Q2Q%42.27%
Revenue Next Year26.48%
Revenue Next 2Y22.48%
Revenue Next 3Y26.68%
Revenue Next 5Y36.89%
EBIT growth 1Y9.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.57%
EBIT Next 3Y20.29%
EBIT Next 5YN/A
FCF growth 1Y8.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-21.52%
OCF growth 3YN/A
OCF growth 5YN/A